| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Repare Therapeutics Inc.$2.65
+0.01 (+0.38%)
C 52Pipeline Score Undervalued Pharma · Clinical
Market Cap
114.24 M
EPS
-1.69
P/E Ratio
-
Value Trade
3.22 M
SEC Financials
Q3 2025Dilution Risk
R&D Expenses
7.50 M
Total Assets
126.75 M
Total Liabilities
11.62 M
Equity
115.13 M
3.52 %
Week
2.32 %
1 Month
50.57 %
3 Month
76.67 %
6 Month
-92.4 %
5 Year
-91.73 %
All Time
Cash Data
Cash Position
112.60 M
Monthly Burn
-
Runway
-
Burn Trend
SEC Filing
Nov 14, 2025
Overview
Volume
1.22 M
52 Week Range
0.89 - 2.66
% held by Insiders
19.6 %
% held by Institutions
37.23 %
Enterprise Value
1.98 M
Total Shares
42.94 M
Short %
1.61 %
Float Shares
27.14 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-31 | Lunresertib and Camonsertib | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-12-31 | Lunresertib and Camonsertib | Phase 1 data readout | Phase 1 | — | – | – | – |
2024-12-31 | Lunresertib and Camonsertib | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
C52
Pipeline Score $1.1B
Pipeline ValueUndervalued
Valuation Signal2
Drugs Scored9.8x
rNPV / MCap Top 81%
Micro Cap (rank 176 of 923)
Percentile RankRepare Therapeutics Inc. carries a moderate pipeline score (52/100), with $4.5B risk-adjusted pipeline value, led by RP-3500 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RP-3500 Small molecule | Solid Tumor | Phase 1 | NCT05566574 | 10% | $4.2B | ACTIVE NOT_RECRUITING | 49 | - | - | Sep 30, 2026 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
lunresertib and camonsertib | endometrial cancer and platinum-resistant ovarian cancer | Phase 1 | 2024-12-12 | overall response rate endometrial cancer: 25.9%; overall response rate ovarian cancer: 37.5%; progression free survival 24 weeks: nearly half of patients Read More | Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Heavily-pretreated patients on lunresertib and camonsertib combin Read More | |
lunresertib and camonsertib | endometrial cancer and platinum-resistant ovarian cancer | Phase 1 | 2024-12-12 | overall response rate endometrial cancer: 25.9%; overall response rate ovarian cancer: 37.5%; progression free survival 24 weeks: nearly half of patients Read More | Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Heavily-pretreated patients on lunresertib and camonsertib combin Read More | |
lunresertib and camonsertib | endometrial cancer and platinum-resistant ovarian cancer | Phase 1 | 2024-12-12 | overall response rate endometrial cancer: 25.9%; overall response rate ovarian cancer: 37.5%; progression free survival 24 weeks: nearly half of patients Read More | Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial Heavily-pretreated patients on lunresertib and camonsertib combin Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RPTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RPTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How RPTX ranks across every disease it competes inCompetitive Position is a premium feature
See how RPTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial